Patiromer is not absorbed and is unlikely to cause systemic toxicity. In animal toxicity studies, no adverse toxicological findings were noted with the exception of gastrointestinal adverse effects noted at in rats doses ?3000 mg/kg.L45798
Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ciprofloxacin | Patiromer can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Patiromer can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metformin | Patiromer can cause a decrease in the absorption of Metformin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Telmisartan | Patiromer can cause a decrease in the absorption of Telmisartan resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisoprolol | Patiromer can cause a decrease in the absorption of Bisoprolol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Carvedilol | Patiromer can cause a decrease in the absorption of Carvedilol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nebivolol | Patiromer can cause a decrease in the absorption of Nebivolol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Patiromer can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Patiromer can cause a decrease in the absorption of Quinidine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiamine | Patiromer can cause a decrease in the absorption of Thiamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |